Innovative tissue engineering strategies for auricular regeneration in microtia: Current advances and future perspectives
Guo Y., Huang Z., Dai D., Lu C., Zou M., Sun C.
Narrative Review, published in Regen Ther (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Regen Ther (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41424615
- PMCID
- PMC12717667
- DOI
- 10.1016/j.reth.2025.08.010
Abstract (original English)
Microtia is a congenital auricular malformation that typically requires reconstructive surgery to restore both form and function. Autologous costal cartilage transplantation remains the clinical standard, yet its invasiveness and donor-site morbidity have driven growing interest in tissue-engineered alternatives. Modern cartilage tissue engineering integrates seed cells, biomaterial scaffolds, and bioactive factors, augmented by emerging technologies such as 3D printing, electrospinning, and dynamic bioreactors. This review summarizes recent progress in auricular reconstruction, with a focus on multilayer scaffold design, diverse cell sources, and advanced bioreactor systems. We emphasize the pivotal role of multi-omics technologies in elucidating the molecular mechanisms underlying chondrogenesis. However, despite substantial progress, clinical translation remains hindered by persistent challenges in replicating the complex architecture of the auricle and achieving long-term stability of engineered cartilage. Optimizing tissue engineering strategies and integrating regenerative medicine with surgical practice may help advance clinical outcomes in microtia treatment.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.